{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:09:24Z","timestamp":1790352564671,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T00:00:00Z","timestamp":1734220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.esmogo.2024.100131","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T14:56:07Z","timestamp":1737212167000},"page":"100131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab\u00a0+ chemotherapy: a RAND\/UCLA modified Delphi panel study"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4062-0808","authenticated-orcid":false,"given":"S.J.","family":"Klempner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8026-7391","authenticated-orcid":false,"given":"R.A.","family":"Pazo-Cid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7593-8138","authenticated-orcid":false,"given":"S.","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6156-123X","authenticated-orcid":false,"given":"M.J.","family":"Arango","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Enzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.H.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3934-0806","authenticated-orcid":false,"given":"G.M.","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-9401","authenticated-orcid":false,"given":"A.","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-W.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":false,"given":"K.","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Ajani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fuldeore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2049-5536","authenticated-orcid":false,"given":"M.S.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmogo.2024.100131_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.esmogo.2024.100131_bib2","author":"Ferlay"},{"issue":"21","key":"10.1016\/j.esmogo.2024.100131_bib3","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","article-title":"Claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing","volume":"21","author":"Niimi","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"23","key":"10.1016\/j.esmogo.2024.100131_bib4","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmogo.2024.100131_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.05.007","article-title":"A\u00a0phase I dose-escalation study of IMAB362 (zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer","volume":"100","author":"Sahin","year":"2018","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100131_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"issue":"10389","key":"10.1016\/j.esmogo.2024.100131_bib7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100131_bib8","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100131_bib9","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1007\/s00432-022-04459-3","article-title":"Immunological effects and activity of multiple doses of zolbetuximab in combination with zoledronic acid and interleukin-2 in a phase 1 study in patients with advanced gastric and gastroesophageal junction cancer","volume":"149","author":"Lordick","year":"2023","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100131_bib10","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/annonc\/mdz199","article-title":"A\u00a0multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study","volume":"30","author":"Tureci","year":"2019","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.esmogo.2024.100131_bib11","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1158\/1078-0432.CCR-23-0204","article-title":"ILUSTRO: Phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma","volume":"29","author":"Klempner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmogo.2024.100131_bib12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2024.42.3_suppl.372","volume":"42","author":"Shitara","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.esmogo.2024.100131_bib13","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in gastric or gastroesophageal junction adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100131_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103663","article-title":"Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials","volume":"9","author":"Lordick","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmogo.2024.100131_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fphar.2018.00245","article-title":"Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae?","volume":"9","author":"Nurgali","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.esmogo.2024.100131_bib16","series-title":"The Rand\/UCLA Appropriateness Method User\u2019s Manual","year":"2001"},{"key":"10.1016\/j.esmogo.2024.100131_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JHL.S352500","article-title":"An adaptation of the RAND\/UCLA modified Delphi panel method in the time of COVID-19","volume":"14","author":"Broder","year":"2022","journal-title":"J\u00a0Healthc Leadersh"},{"key":"10.1016\/j.esmogo.2024.100131_bib18","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Antiemesis V.2.2024. Available at NCCN.org. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/antiemesis.pdf. Accessed September 30, 2024."},{"key":"10.1016\/j.esmogo.2024.100131_bib19","series-title":"Northbrook, IL: Astellas Pharma US","year":"2024"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100131_bib20","first-page":"232","article-title":"Chemotherapy-induced nausea and vomiting: optimizing prevention and management","volume":"5","author":"Rao","year":"2012","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.esmogo.2024.100131_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejca.2023.03.025","article-title":"Position statement on the management of the immune checkpoint inhibitor-induced colitis via multidisciplinary modified Delphi consensus","volume":"187","author":"Desmedt","year":"2023","journal-title":"Eur J Cancer"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294981982400092X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S294981982400092X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:47:02Z","timestamp":1753235222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S294981982400092X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":21,"alternative-id":["S294981982400092X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100131","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus guidance for prevention and management of nausea and vomiting in patients treated with zolbetuximab\u00a0+ chemotherapy: a RAND\/UCLA modified Delphi panel study","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100131","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100131"}}